CTAF Academy: Update 01, Feb 2021
The treatment of arrythmias is one of the most dynamic and fastest evolving fields in medicine. These advances bring new hope for a better quality of life for many patients.
The focus has shifted from managing the complications of arrythmias to treating the origin of the problem, from merely pacing empirically in the past, to creating synchronised contractions (and thus avoiding the medium to longterm complications of traditional pacing), and to use smaller and smarter devices. In the hands of an experienced electrophysiologist, both safety and efficacy of procedures are high.
We aim to bring you up-to-date with the latest evidence-based advances in electrophysiology and treatment of arrythmias in easy-to-read short articles highligting the key points to assist you in your decision making.
All the best
The CTAFC team.
Key point summaries
“Catheter ablation has been placed front and centre in the latest guidelines for the management of supraventricular tachycardia (SVT) from the European Society of Cardiology (ESC). Moreover, the guidelines have dropped a whole host of medications that were once considered part of standard care for managing this family of arrhythmic conditions.” – Medscape, ESC Conference, Paris. READ MORE
Patients with a bradycardia or conduction system disease, can now be paced more effectively with a procedure referred to as His Bundle Pacing (HBP). Read why HBP is hailed as the ‘pacing of the future’. READ MORE
Cryoablation has revolutionised the treatment of patients with atrial fibrillation. The procedure is quick, relatively painless and allows for short hospital stays. The incidence of post ablation cardiac arrhythmias is exceedingly rare. For best patient outcomes, patients with AF should be cryo-ablated sooner rather than later. READ MORE
Which patients should be considered for the smallest cardiocapsule? With this small device no chest scar or visible bump is noticeable and it allows for fewer post-implant activity restrictions. The evidence supports that systemic infections or dislodgements related to the device are highly unlikely with a very low revision rate, if at all necessary. READ MORE.
ICD therapy show mortality reduction and benefit in both primary and secondary prevention of sudden cardiac deaths. The device is strongly considered particularly in young patients and those with life expectancy exceeding 10 years. READ MORE.
Approximately 1 out of every 15 persons suffer from obstructive sleep apnoea; unfortunately, more than half of these patients will remain undiagnosed. It is important to note that recent reports suggest sleep apnoea may reduce one’s lifespan by almost 20 years. READ MORE.